Close Menu
Trade Verdict
  • Home
  • Latest News
  • Investing
  • Personal Finance
  • Retirement
  • Economy
  • Stocks
  • Bonds
  • Commodities
  • Cryptocurrencies

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Hispania Sources Pronounces Replace to Proposed Non-public Placement

October 27, 2025

15 Finest Recurring Income Enterprise Concepts

October 27, 2025

Janus Henderson AAA CLO ETF Q3 2025 Commentary (JAAA)

October 27, 2025
Facebook X (Twitter) Instagram
Trade Verdict
  • Latest News
  • Investing
  • Personal Finance
  • Retirement
  • Economy
Facebook X (Twitter) Instagram
Trade Verdict
Home»Stocks»Roivant Sciences Ltd. – Immunovant Batoclimab Graves’ Illness Proof-of-Idea Research
Stocks

Roivant Sciences Ltd. – Immunovant Batoclimab Graves’ Illness Proof-of-Idea Research

EditorialBy EditorialSeptember 4, 2025No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Roivant Sciences Ltd. – Immunovant Batoclimab Graves’ Illness Proof-of-Idea Research
Share
Facebook Twitter LinkedIn Pinterest Email


Convention Name Members

Samuel Slutsky – LifeSci Capital, LLC, Analysis Division
Yatin Suneja – Guggenheim Securities, LLC, Analysis Division
Samantha Lynn Semenkow – Citigroup Inc. Trade Analysis
David Risinger – Leerink Companions LLC, Analysis Division
Yaron Werber – TD Cowen, Analysis Division
Yasmeen Rahimi – Piper Sandler & Co., Analysis Division
Leland Gershell – Oppenheimer & Co. Inc., Analysis Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Analysis Division
Sean Kim – JPMorgan Chase & Co, Analysis Division
Georgia Calhoun
Jason Gerberry – BofA Securities, Analysis Division
Charles Ndiaye – Stifel, Nicolaus & Firm, Integrated, Analysis Division
Nathanael Charoensook – Leerink Companions LLC, Analysis Division
Corinne Jenkins – Goldman Sachs Group, Inc., Analysis Division

Presentation

Operator

Good day, and thanks for standing by. Welcome to the Immunovant Graves’ Illness Information Replace Name. [Operator Instructions] Please be suggested that at the moment’s convention is being recorded. I’d now like at hand the decision over to your first speaker at the moment, Stephanie Lee. Please go forward.

Stephanie Lee Griffin
Chief Working Officer of Roivant Platforms

Good afternoon, and thanks for becoming a member of at the moment’s name to assessment the Immunovant Graves’ illness knowledge. I am Stephanie Lee with Roivant. Presenting at the moment, we have now Matt Gline, CEO of Roivant.

For these dialing in by way of convention name, you could find the slides being introduced at the moment in addition to the press launch saying these updates on our IR web site at www.investor.roivant.com. We’ll even be offering the present slide numbers as we current that can assist you observe alongside.

I wish to remind you that we’ll be guaranteeing forward-looking statements throughout at the moment’s presentation. We strongly encourage you to assessment the data that we have now filed with the SEC for extra

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Editorial
  • Website

Related Posts

Janus Henderson AAA CLO ETF Q3 2025 Commentary (JAAA)

October 27, 2025

UBS sees ‘finest alternatives’ in Asia, bonds and gold

October 27, 2025

Politics And The Markets 10/27/25

October 27, 2025

China’s industrial earnings surge 21.6% in September, greatest leap in almost two years

October 27, 2025
Add A Comment
Leave A Reply Cancel Reply

Trending Posts

Hispania Sources Pronounces Replace to Proposed Non-public Placement

October 27, 2025

15 Finest Recurring Income Enterprise Concepts

October 27, 2025

Janus Henderson AAA CLO ETF Q3 2025 Commentary (JAAA)

October 27, 2025

Ferrari goals at AI era with crypto public sale for Le Mans automobile

October 27, 2025
More News
Stocks

Janus Henderson AAA CLO ETF Q3 2025 Commentary (JAAA)

By Editorial
Stocks

UBS sees ‘finest alternatives’ in Asia, bonds and gold

By Editorial
Stocks

Politics And The Markets 10/27/25

By Editorial
Trade Verdict
Facebook X (Twitter) Instagram Pinterest
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms Of Service
© 2025 Trade Verdict. All rights reserved by Trade Verdict.

Type above and press Enter to search. Press Esc to cancel.